Apellis Pharmaceuticals Shares Outstanding 2016-2021 | APLS

Apellis Pharmaceuticals shares outstanding from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Apellis Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2020 75
2019 62
2018 54
2017 14
2016 8
2015 6
Apellis Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 81
2021-03-31 79
2020-12-31 75
2020-09-30 76
2020-06-30 76
2020-03-31 74
2019-12-31 62
2019-09-30 64
2019-06-30 63
2019-03-31 58
2018-12-31 54
2018-09-30 56
2018-06-30 55
2018-03-31 50
2017-12-31 14
2017-09-30 8
2017-06-30 8
2017-03-31 8
2016-12-31
2016-09-30 8
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.732B $0.251B
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29